Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Maze TherapeuticsMAZE +2.76%16 Debt-to-Equity is 0.13 as of Jun. 2026, which is 117% above its 10-year median of 0.06. GuruFocus rates MAZE with a GF Score™ of 16/100. The stock has 3 warning signs investors should review. Among 965 Biotechnology companies, Maze Therapeutics ranks better than 54.2% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Maze Therapeutics's Debt-to-Equity or its related term are showing as below:
MAZE'
s Debt-to-Equity Range Over the Past 10 Years
Min: -0.29 Med: 0.06 Max: 0.18
Current: 0.13
During the past 4 years, the highest Debt-to-Equity Ratio of Maze Therapeutics was 0.18. The lowest was -0.29. And the median was 0.06.
MAZE's Debt-to-Equity is ranked better than 54.2% of 965
companies
in the Biotechnology industry
Industry Median: 0.15
vs MAZE: 0.13
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Maze Therapeutics Debt-to-Equity Related Terms
Maze Therapeutics Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Maze Therapeutics's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MAZE vs NTLA, RXRX, SEPN: Debt-to-Equity Comparison
For the Biotechnology subindustry, Maze Therapeutics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Maze Therapeutics Debt-to-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Maze Therapeutics's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Maze Therapeutics's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Maze Therapeutics (MAZE) has a Debt-to-Equity of 0.13 as of Jun. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Maze Therapeutics and its competitors. This is 117% above median its historical median of 0.06. According to the industry distribution chart, Maze Therapeutics ranks #442 out of 965 companies in the Biotechnology industry, placing it in the top 45.8%.
Is Maze Therapeutics' Debt-to-Equity too high?
Maze Therapeutics' current Debt-to-Equity of 0.13 is 117% above median its 10-year median of 0.06. The Biotechnology industry median Debt-to-Equity is 0.15. Maze Therapeutics' value of 0.13 is 13.3% below this industry median. Based on the distribution chart, Maze Therapeutics ranks #442 out of 965 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Maze Therapeutics has a GF Score™ of 16/100, reflecting its overall financial health beyond just this single metric.
How does Maze Therapeutics' Debt-to-Equity compare to NTLA and RXRX?
According to the Biotechnology industry distribution chart, Maze Therapeutics ranks #442 out of 965 companies for Debt-to-Equity. This puts Maze Therapeutics in the upper half of its industry. The industry median Debt-to-Equity is 0.15. Maze Therapeutics' value of 0.13 is 13.3% below this benchmark. While the company's 10-year median is 0.06 vs. the industry median of 0.15, Maze Therapeutics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.15, based on 965 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Maze Therapeutics's current Debt-to-Equity of 0.13 is 13.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Maze Therapeutics and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.15 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Maze Therapeutics's current Debt-to-Equity is 0.13, which is 117% above median its own 10-year median of 0.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Maze Therapeutics stock overvalued right now?
Maze Therapeutics (MAZE) has a current Debt-to-Equity of 0.13. The current Debt-to-Equity is 0.13, which is 117% above median its 10-year median of 0.06 and 13.3% below the Biotechnology industry median of 0.15. Maze Therapeutics' overall GF Score™ is 16/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Maze Therapeutics (MAZE), the current Debt-to-Equity is 0.13 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Maze Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small-molecule precision medicines for patients living with renal, cardiovascular, and related metabolic, or CVRM, diseases, including obesity. The company is advancing a pipeline using its Compass platform, which allows the company to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process it refers to as variant functionalization. It is currently advancing two programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach for chronic kidney disease, or CKD.
16GF Score
Get the complete analysis for MAZE
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MAZE has been successfully added to your 
